Deal Lab · Buyout model 1.0
Novo Nordisk A/S Buyout Model
The buyout model of Novo Nordisk A/S on its published figures, in Danish kroner.
Inputs Missing
The model of this company does not run on its published figures, which leave out the following. No figure stands in for a missing input.
- Payables: no payables are published at the end of the base period.
- Payments of lease liabilities: no payments of lease liabilities are published for the base period.
Inputs and Their Documents
Published figures of fiscal 2025, each with the documents it comes from.
| Input | Value | Method | Documents |
|---|---|---|---|
| Adjusted EBITDA | DKK151bn | Adjusted EBITDA of the company page | 20-F 2025-12 |
| Share-based pay | DKK1.4bn | Share-based pay that adjusted EBITDA adds back | 20-F 2025-12 |
| EBITDA after share-based pay | DKK150bn | Adjusted EBITDA less share-based pay | 20-F 2025-12 |
| Depreciation and amortisation | DKK22.0bn | Depreciation and amortisation of adjusted EBITDA | n/a |
| Revenue | DKK309bn | Revenue of the base period | 20-F 2025-12 |
| Borrowings | DKK131bn | Total debt less lease liabilities | 20-F 2025-12 |
| Lease liabilities | DKK8.6bn | Lease liabilities | 20-F 2025-12 |
| Cash and short-term investments | DKK26.5bn | Cash and short-term investments | 20-F 2025-12 |
| Non-controlling interests | DKK0 | The balance sheet reports none | n/a |
| Receivables | DKK70.9bn | Receivables | 20-F 2025-12 |
| Inventories | DKK49.6bn | Inventories | 20-F 2025-12 |
| Interest on lease liabilities | DKK416m est. | Interest on lease liabilities at the average rate of finance costs on total debt | 20-F 2025-12 |
| Capital expenditure | DKK60.1bn | Capital expenditure of the latest fiscal year | 20-F 2025-12 |
Deal Lab computes arithmetic on published figures and on the assumptions of the user. It values no company, recommends no transaction and forecasts no result.